Abstract: Polymorphs of 3-chloro-4[(2R)-2-(4-chlorophenyl)-4-[(1R)-1-(4-cyanophenyl)ethyl]-1-piperazinyl]-benzonitrile are disclosed, as well as pharmaceutical compositions comprising said polymorphs, methods of using the polymorphs, and a process for preparing them.

Abstract: A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: The invention comprises compounds of Formula 1: wherein, R1 is independently H or halogen; R2 is, for example, H or —R10—NR11R12, and wherein R10 is C1-C6 alkyl, and R11 and R12 are independently H, C1-C4 alkyl, and hydrates, solvates, salts and tautomers thereof. The invention further comprises methods for making the compounds of the invention and methods for making compounds useful in the treatment or prevention of cardiac arrhythmia from the compounds of the invention.

Abstract: A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: This invention discloses a novel method for the conversion of carboxylic acids to carbothioic acids and application of the method to the preparation of androstane carbothiolates, such as fluticasone propionate, which avoids column chromatography.

Abstract: This invention discloses a novel method for the conversion of carboxylic acids to carbothioic acids and application of the method to the preparation of androstane carbothiolates, such as fluticasone propionate, which avoids column chromatography.

Abstract: A compound of the formula: 1

Abstract: A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: This invention discloses a novel method for the conversion of carboxylic acids to carbothioic acids and application of the method to the preparation of androstane carbothiolates, such as fluticasone propionate, which avoids column chromatography.

Abstract: In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2′-substituted and optionally 4″-substituted 9-oxime erythromycin derivatives with an alkylating agent in the presence of a palladium catalyst and phosphine. In another aspect, the invention relates to processes for preparing 6-O-substituted erythromycin ketolides using the palladium-catalyzed alkylation reaction.

Abstract: A compound of the formula: 1

Abstract: A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: A process is disclosed for the preparation of N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-amino acid derivatives.

Abstract: A process is disclosed for the preparation of an N-acylated activated derivative of an amino acid or a salt thereof.

Abstract: Processes are disclosed for the preparation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)car bonyl)-L-valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhex ane or an acid addition salt thereof and (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)-D-valinyl)amino)-2-(N-((5-thiazolyl) methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or an acid addition salt thereof.

Abstract: Divalent ion tolerant aromatic sulfonate suitable for enhanced oil recovery characterized by the formula: ##STR1## where x=0 to 4R'=H or Ch.sub.3R=CH.sub.3 (CH.sub.2)y and y=1 to 15. Preferably, the compositioncomprises of second compound characterized by the formula ##STR2## wherein R, x, y, and R' are the same as defined in claim 1.

Abstract: Divalent ion tolerant aromatic sulfonate suitable for enhanced oil recovery characterized by the formula: ##STR1## wherein x=0 to 4R'=H or CH.sub.3R=CH.sub.3 (CH.sub.2)y and y=1 to 15. Preferably, the composition comprises of second compound characterized by the formula ##STR2## wherein R, x, y, and R' are the same as defined in claim 1.

Abstract: A new catalyst system for the conversion of short-chain aliphatic alcohols to hydrocarbon having the formula[M].sup.m+ [X.sup.p+ Y.sub.a Z.sub.12-a O.sub.40 ].sup.-(8-p)wherein M is selected from at least one element from Group IIIA including lanthanides and actinides, or mixtures thereof,X is at least one element selected from P, Si, As, Ti, Zr, B, Co, Cu or Sn,Y and Z are independently selected from W, Mo, or V, P=is the valence of X usually within 2 to 5,m=8-pO<a.ltoreq.12.

Abstract: A new catalyst system for the conversion of short-chain aliphatic alcohols to hydrocarbons having the formula[ML.sub.q ].sub.b.sup.m+ [N].sub.d.sup.n+ [X.sup.p+ Y.sub.a Z.sub.(12-a) O.sub.40 ].sup.-(8-p)wherein:[ML] is an organometallic compound where M is at least one metal selected from Group IIIA, IVA, VA, IB, IIB, IVB, VB, VIA, Fe, Co, and Ni; and L is an organic ligand,N is a positively charged species including a positively charged organic ligand,X is at least one element selected from P, Si, As, Ti, Zr, B, Co, Cu or Sn,Y and Z are independently selected from W, Mo, or V,m+n=[-pq=1-6O<a.ltoreq.12O.ltoreq.d<3b=1 to 3.

Abstract: A new catalyst system for the conversion of short-chain aliphatic alcohols to hydrocarbons having the formula[ML.sub.q ].sub.b.sup.m+ [N].sub.d.sup.n+ [X.sup.p+ Y.sub.a Z.sub.(12-a) O.sub.40 ].sup.-(8-p)wherein:[ML] is an organometallic compound where M is at least one metal selected from Group IIIA, IVA, VA, IB, IIB, IVB, VB, VIA, Fe, Co, and Ni; and L is an organic ligand,N is a positively charged species including a positively charged organic ligand,X is at least one element selected from P, Si, As, Ti, Zr, B, Co, Cu or Sn,Y and Z are independently selected from W, Mo, or V,m+n=8-pq=1-6O<a.ltoreq.12O.ltoreq.d<3b=1 to 3.